Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.45B P/E 15.65 EPS this Y -43.40% Ern Qtrly Grth -10.20%
Income 115.91M Forward P/E 15.47 EPS next Y 6.20% 50D Avg Chg 7.00%
Sales 1.53B PEG -0.66 EPS past 5Y 9.86% 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.23 EPS next 5Y -18.32% 52W High Chg -33.00%
Recommedations 2.60 Quick Ratio 2.87 Shares Outstanding 107.64M 52W Low Chg 18.00%
Insider Own 1.12% ROA 2.16% Shares Float 108.01M Beta 0.60
Inst Own 17.00% ROE 8.93% Shares Shorted/Prior 8.13M/9.43M Price 13.30
Gross Margin 50.64% Profit Margin 3.97% Avg. Volume 956,414 Target Price 11.40
Oper. Margin 16.59% Earnings Date - Volume 634,963 Change -0.60%
About Veradigm Inc.

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Veradigm Inc. News
11/21/24 Veradigm Launches an Ambient Scribe Advancement to Ease the Healthcare Administrative Burden
11/19/24 Veradigm Advancing Point of Care Engagement Through Payer-Provider Collaboration
10/10/24 Veradigm Advances Deeper Clinical Insights Through NLP-Enhanced EHR Data
10/03/24 Automated Medical Chart Retrieval Expands to 300,000+ U.S. Healthcare Providers via Veradigm eChart Courier
09/26/24 Veradigm Ranked Top Vendor by KLAS
08/29/24 Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions
08/06/24 Positive Impact Observed at Many Orthopedic Practices Utilizing Veradigm Coding Services
06/12/24 Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024
05/30/24 Veradigm Payerpath Rated Highest in Client Satisfaction
05/28/24 Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance
05/28/24 Veradigm Announces Leadership Updates
04/09/24 Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings
03/14/24 Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
03/13/24 Veradigm Announces Initial Financial Guidance for Fiscal 2024
03/04/24 Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference
03/04/24 Veradigm Completes Acquisition of ScienceIO
02/28/24 Sprinklr Set to Join S&P SmallCap 600
02/28/24 Veradigm to Participate in TD Cowen Annual Health Care Conference
02/28/24 Veradigm Receives Expected Delisting Notice from Nasdaq
02/27/24 Veradigm Inc (MDRX) Announces Strategic Acquisition of ScienceIO to Enhance AI Capabilities
MDRX Chatroom

User Image IOMASS Posted - 23 hours ago

$MDRX a lil action today but not much volume - maybe recent PRs constitute signal that transaction is pending...

User Image LordWellesley Posted - 1 day ago

The sky is the limit with Veradigm $MDRX once the financial reporting mess is solved. Fix it major Tom..!! https://www.linkedin.com/pulse/veradigms-strategic-acquisitions-driving-innovation-data-junaid-h06sf?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

User Image LordWellesley Posted - 2 days ago

Just keep silent and all will… disappear. Tnx major Tom $MDRX Veradigm

User Image IOMASS Posted - 2 days ago

$MDRX Price leaking on diminished volume after trading to $11+ on big volume on company sale process update - FWIW most recent DB report gave expected sales price of $12- $15 per share...

User Image LordWellesley Posted - 1 week ago

Looks like Veradigm is running out of (net) cash pretty fast. Now only 95 mln remaining which looks like a 40 mln drawdown in 6 months time… Could be partly a working cap matter but they mention the cost of cleaning up the admin mess and the advisory cost of the strategic review. Cash from ops apparently can’t cover this. Getting more mediocre everytime I look at it. Hurry up Mr Tom. $MDRX

User Image IOMASS Posted - 1 week ago

$MDRX Looks like $11.30 is the new clearing price - up a nickel with volume slowing down...

User Image LordWellesley Posted - 1 week ago

The Veradigm acquisition will be a game changer for McKesson $MCK $MDRX

User Image ccdemuth Posted - 1 week ago

$MDRX https://seekingalpha.com/article/4736143-veradigm-and-the-2025-m-and-a-boom

User Image IOMASS Posted - 1 week ago

$MDRX FWIW DB raised PT to $12, Stephens reit $13 PT and TD Cowen reit $15 PT post the recent report...

User Image IOMASS Posted - 1 week ago

$MDRX Looks like accumulation level $11.25 now but price bouncing around a bit - volume now solid....

User Image trufflehog Posted - 1 week ago

$MDRX finally break 10

User Image IOMASS Posted - 1 week ago

$MDRX Well at least someone thinks the new update is credible - not much volume but likely not many shares available...

User Image LordWellesley Posted - 1 week ago

@IOMASS This is the Veradigm article. Quite specific about the impending deal but in essence news that was reported earlier. Let’s see. $MDRX $ORCL $SPY

User Image IOMASS Posted - 1 week ago

$MDRX Report out re finalists in auction process, deal expected by Thanksgiving - hopeful…

User Image IOMASS Posted - 2 weeks ago

$MDRX 150K shares traded @ $1.50 up a dime - Drumpf stock I guess!

User Image IOMASS Posted - 2 weeks ago

$MDRX looks like continued accumulation @ $9.40 - yawn..

User Image IOMASS Posted - 3 weeks ago

$MDRX Notable volume this morn again @ $9.40 level - should just ignore it until news released but sure seems someone thinks they know more than publicly available...

User Image IOMASS Posted - 10/31/24

$MDRX No rhyme, no reason but someone buying a potful of shares @ $9.40 today...

User Image IOMASS Posted - 10/29/24

$MDRX It appears top hedge fund ownership is still around 40% so given the quiet I would have to assume progress is being made on the strategic review front - impressive trading day today!

User Image LordWellesley Posted - 10/27/24

The future of healthcare and innovative (and less costly) pharma development is here. And it is pioneered by the Veradigm $MDRX team. So far so good. But… why can’t this cutting edge company fix its financial reporting? https://veradigm.com/veradigm-news/real-world-data-for-healthcare-guide/ $SPY $XLV

User Image LordWellesley Posted - 10/25/24

@IOMASS News is NEVER pending with #Veradigm that’s exactly the problem 😅 $MDRX

User Image IOMASS Posted - 10/25/24

$MDRX the volume up near $10 is pretty low but don't see a reason for the increased activity today - it's not like news is pending!!!

User Image LordWellesley Posted - 1 month ago

$MDRX Veradigm is becoming such a sad little story. No movement, no real news, nothing whatsoever. Lots of upbeat commercial news items and other tidbits for sure. But nothing to deserve any level of confidence from Street professionals or ordinary shareholders for that matter. A sinking feeling, Mr Langan.

User Image IOMASS Posted - 1 month ago

$MDRX talk about investor fatigue!

User Image LordWellesley Posted - 1 month ago

$MDRX it’s now 7️⃣0️⃣6️⃣ days since Veradigm filed a financial report that was in line with SEC regulations. Delisted and in the OTC since bin for 7 months plus already. Dozens of very well paid executives are to blame here with CEO Mr Tom Langan totally silent (except in his silly LinkedIn cheerleader messages). No updates, no news, nothing.

User Image LordWellesley Posted - 1 month ago

Veradigm $MDRX stock price is gently eroding in the OTC sin bin. Management apparently is taking its time, ‘diligently’ creating a new structure that will mainly benefit themselves. No need to file results. Just let ik sink and reap the benefits.

User Image IOMASS Posted - 1 month ago

$MDRX PR out today, it’s alive!!

User Image IOMASS Posted - 1 month ago

@TheYoungerPliny Might be an interesting reverse merger candidate for $MDRX

User Image LordWellesley Posted - 1 month ago

Two years ago Francisco Partners acquired #Merative from IBM (Watson). Today a combination with #Veradigm $MDRX would create an unparalleled powerhouse in big pharma research. https://www.merative.com/

User Image LordWellesley Posted - 09/29/24

Interesting read about how AI and machine learning can help pharma companies maintain or regain their profitability $MDRX $IHE $LLY https://www.cnbc.com/2024/09/29/the-one-sector-of-the-stock-market-that-is-cheap-with-upside-today.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

Analyst Ratings
TD Cowen Buy May 28, 24
Deutsche Bank Hold Mar 19, 24
RBC Capital Outperform Jan 19, 24
Barclays Equal-Weight Jan 3, 24
Stephens & Co. Equal-Weight Nov 14, 23
Stephens & Co. Equal-Weight Oct 10, 23
Argus Research Hold Jul 6, 23
Stephens & Co. Equal-Weight Apr 12, 23
Piper Sandler Neutral Feb 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jones Leah Chief Financial Offi.. Chief Financial Officer Aug 15 Sell 17.65 3,945 69,629 109,055 08/18/22
Poulton Richard J. CEO CEO Aug 15 Sell 17.45 20,000 349,000 732,517 08/16/22
Black Paul Director Director Jun 10 Sell 16.5816 60,000 994,896 1,254,631 06/13/22
Black Paul Director Director Jun 06 Sell 17.33 140,450 2,433,998 1,314,631 06/07/22
Black Paul Director Director May 17 Sell 18.1792 50,000 908,960 1,529,649 05/19/22
Black Paul Director Director May 13 Sell 18.0138 50,000 900,690 1,579,649 05/16/22
Black Paul CEO CEO Mar 10 Sell 21.8676 60,000 1,312,056 1,389,199 03/10/22
Poulton Richard J. President & CFO President & CFO Feb 15 Sell 20.78 20,000 415,600 521,593 02/16/22